A phase II clinical trial of neoadjuvant chemotherapy combined with immunotherapy and different radiotherapy fractionation regimens in HR+/HER2- breast cancer - Top-Institutions - MDSpire

A phase II clinical trial of neoadjuvant chemotherapy combined with immunotherapy and different radiotherapy fractionation regimens in HR+/HER2- breast cancer

  • By

  • Jie Lan

  • Xiaoyue Sun

  • Xiaobo Huang

  • Yanxia Zhao

  • Zhuofei Bi

  • Wei Huang

  • Tin Luo

  • Jing Jing

  • Xin Wu

  • Lei Liu

  • July 9, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Netherlands Cancer Institute
    Netherlands Cancer Institute

    Amsterdam, North Holland

    Key Differentiators

    • Oncology

Original Source(s)

A phase II clinical trial of neoadjuvant chemotherapy combined with immunotherapy and different radiotherapy fractionation regimens in HR+/HER2- breast cancer

  • by Jie Lan, Xiaoyue Sun, Xiaobo Huang, Yanxia Zhao, Zhuofei Bi, Wei Huang, Tin Luo, Jing Jing, Xin Wu, Lei Liu

  • July 9, 2026

Related Content

Inside the Rise of circRNA

Circio CEO Erik Wiklund reflects on the discovery of human circular RNA and its evolution into a fast-moving therapeutic modality

  • July 9, 2026

  • 12 min
The use of motion tracking technology to support an exercise intervention for children and young people with cancer: perspectives of users and healthcare professionals in the FORTEe trial

Sequential gemcitabine–docetaxel in BCG-naïve and BCG-failure non–muscle-invasive bladder cancer: a systematic review and meta-analysis